Compare Glenmark Pharma with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs JUBILANT LIFE SCIENCES - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA JUBILANT LIFE SCIENCES GLENMARK PHARMA/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 11.6 15.4 75.2% View Chart
P/BV x 1.5 1.7 86.1% View Chart
Dividend Yield % 0.7 0.9 78.4%  

Financials

 GLENMARK PHARMA   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
JUBILANT LIFE SCIENCES
Mar-19
GLENMARK PHARMA/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs712898 79.2%   
Low Rs484618 78.3%   
Sales per share (Unadj.) Rs349.6572.0 61.1%  
Earnings per share (Unadj.) Rs32.836.2 90.5%  
Cash flow per share (Unadj.) Rs44.359.5 74.5%  
Dividends per share (Unadj.) Rs2.004.50 44.4%  
Dividend yield (eoy) %0.30.6 56.4%  
Book value per share (Unadj.) Rs198.6301.9 65.8%  
Shares outstanding (eoy) m282.17159.28 177.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.71.3 129.0%   
Avg P/E ratio x18.220.9 87.2%  
P/CF ratio (eoy) x13.512.7 105.9%  
Price / Book Value ratio x3.02.5 119.9%  
Dividend payout %6.112.4 49.1%   
Avg Mkt Cap Rs m168,625120,694 139.7%   
No. of employees `00012.02.4 503.6%   
Total wages/salary Rs m20,56119,260 106.8%   
Avg. sales/employee Rs Th8,196.038,120.6 21.5%   
Avg. wages/employee Rs Th1,708.18,058.4 21.2%   
Avg. net profit/employee Rs Th768.52,414.3 31.8%   
INCOME DATA
Net Sales Rs m98,65591,108 108.3%  
Other income Rs m2,081357 582.4%   
Total revenues Rs m100,73691,466 110.1%   
Gross profit Rs m15,85817,390 91.2%  
Depreciation Rs m3,2593,709 87.9%   
Interest Rs m3,3462,198 152.2%   
Profit before tax Rs m11,33511,840 95.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,672-2,802 -59.7%   
Tax Rs m3,7563,268 114.9%   
Profit after tax Rs m9,2505,770 160.3%  
Gross profit margin %16.119.1 84.2%  
Effective tax rate %33.127.6 120.1%   
Net profit margin %9.46.3 148.0%  
BALANCE SHEET DATA
Current assets Rs m66,96845,848 146.1%   
Current liabilities Rs m40,21120,897 192.4%   
Net working cap to sales %27.127.4 99.0%  
Current ratio x1.72.2 75.9%  
Inventory Days Days8357 146.7%  
Debtors Days Days8151 159.4%  
Net fixed assets Rs m33,32265,498 50.9%   
Share capital Rs m282159 177.2%   
"Free" reserves Rs m55,77047,930 116.4%   
Net worth Rs m56,05248,089 116.6%   
Long term debt Rs m35,73842,429 84.2%   
Total assets Rs m132,888114,685 115.9%  
Interest coverage x4.46.4 68.7%   
Debt to equity ratio x0.60.9 72.3%  
Sales to assets ratio x0.70.8 93.5%   
Return on assets %9.56.9 136.4%  
Return on equity %16.512.0 137.5%  
Return on capital %17.812.4 143.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m62,99812,422 507.2%   
Fx outflow Rs m22,85917,227 132.7%   
Net fx Rs m40,140-4,805 -835.4%   
CASH FLOW
From Operations Rs m13,24211,215 118.1%  
From Investments Rs m-6,990-10,118 69.1%  
From Financial Activity Rs m-7,3876,574 -112.4%  
Net Cashflow Rs m-2,9717,612 -39.0%  

Share Holding

Indian Promoters % 48.3 45.6 105.9%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 6.9 8.7 79.3%  
FIIs % 34.4 21.2 162.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 21.1 49.8%  
Shareholders   56,727 23,815 238.2%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   FRESENIUS KABI ONCO.  AJANTA PHARMA  ALEMBIC LTD  ALEMBIC PHARMA  ELDER PHARMA  

Compare GLENMARK PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens in Green; FMCG and Metal Stocks Gain(09:30 am)

Asian stock markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 2% while the Hang Seng is down 0.3%.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY20); Net Profit Down 24.0% (Quarterly Result Update)

Feb 1, 2020 | Updated on Feb 1, 2020

For the quarter ended December 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 24.0% YoY). Sales on the other hand came in at Rs 23 bn (down 2.6% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY20); Net Profit Up 18.9% (Quarterly Result Update)

Oct 31, 2019 | Updated on Oct 31, 2019

For the quarter ended September 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 18.9% YoY). Sales on the other hand came in at Rs 23 bn (down 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

The Next Few Days Are Crucial for Smallcap Investors - And 3 Must-Buy Stocks(Profit Hunter)

Feb 19, 2020

While I have been writing about the rebound in smallcaps for quite some time now... I have shied from the question - When exactly is the smallcap rebound happening. Well, the answer is now.

Here's Why I Recommended 15 Stocks in One Day Flat(Views On News)

Feb 14, 2020

This proven strategy can give big returns in quick time.

The Top 8 Trading Mistakes You Should Avoid(Fast Profits Daily)

Feb 18, 2020

Avoid these mistakes and your trading will turn much more profitable.

These Rebirth of India Stocks Are Raring to Compete with Tesla(The 5 Minute Wrapup)

Feb 17, 2020

There are Indian stocks which can soar like Tesla in the long-run.

Corona Virus Could Trigger a Rally in this Stock(Profit Hunter)

Feb 20, 2020

A company which benefits from crude oil and coronavirus - if you would like to know more about it read this.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Feb 25, 2020 11:39 AM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - ORCHID PHARMA LTD COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS